05/16/2024 7:05 AM | Akari Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/15/2024 3:47 PM | Akari Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/01/2024 4:27 PM | Akari Therapeutics (Subject)
| Form 425 | |
05/01/2024 4:04 PM | Akari Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/30/2024 8:45 PM | Akari Therapeutics (Issuer) Jacques Rachelle Suzanne (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/11/2024 5:30 AM | Akari Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/01/2024 5:30 AM | Akari Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
|
03/29/2024 3:15 PM | Akari Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/11/2024 4:25 PM | Akari Therapeutics (Subject)
| Form 425 | |
03/11/2024 4:24 PM | Akari Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/05/2024 7:28 AM | Akari Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/05/2024 7:34 AM | Akari Therapeutics (Subject)
| Form 425 | |
01/09/2024 4:25 PM | Akari Therapeutics (Filer)
| Form D Notice of Exempt Offering of Securities | |
01/04/2024 11:34 AM | Akari Therapeutics (Subject) RPC Pharma Ltd (Filed by)
| Form SC 13D/A | |
01/02/2024 7:00 PM | Akari Therapeutics (Issuer) DICICCO WENDY F (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2024 7:06 PM | Akari Therapeutics (Issuer) Jacques Rachelle Suzanne (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2024 6:56 PM | Akari Therapeutics (Issuer) Patel Samir Rashmikant (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2024 6:49 PM | Akari Therapeutics (Issuer) Hashad Mohamed Wa'el Ahmed (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2024 5:58 PM | Akari Therapeutics (Issuer) Prudo-Chlebosz Raymond (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2024 5:35 PM | Akari Therapeutics (Issuer) WILLIAMS DONALD A (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
01/02/2024 5:41 PM | Akari Therapeutics (Issuer) Grissinger Michael (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
12/01/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/16/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/27/2023 3:15 PM | Akari Therapeutics (Filer)
| Form 424B3 | |
10/26/2023 11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
10/23/2023 11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
10/23/2023 11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
10/20/2023 4:00 PM | Akari Therapeutics (Subject) RPC Pharma Ltd (Filed by)
| Form SC 13D/A | |
10/20/2023 3:28 PM | Akari Therapeutics (Filer)
| Form POS AM | |
10/20/2023 3:29 PM | Akari Therapeutics (Filer)
| Form POS AM | |
10/20/2023 3:23 PM | Akari Therapeutics (Filer)
| Form F-3 Registration statement for securities of certain foreign private issuers | |
10/19/2023 3:17 PM | Akari Therapeutics (Filer)
| Form D Notice of Exempt Offering of Securities | |
10/12/2023 3:43 PM | Akari Therapeutics (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
09/29/2023 7:01 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/21/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/05/2023 8:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/18/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/17/2023 3:27 PM | Akari Therapeutics (Subject) Deutsche Bank Trust Co Americas/ ADR Group (Filed by)
| Form F-6 POS | |
08/15/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/02/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/27/2023 7:00 AM | Akari Therapeutics (Filer) Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
This military-backed stock “owns” AI market (Ad) The AI boom is just getting started.
And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. |
07/25/2023 7:30 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/19/2023 7:00 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/13/2023 7:30 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/11/2023 7:30 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/06/2023 7:30 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/05/2023 7:30 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/30/2023 3:30 PM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/06/2023 11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
06/06/2023 11:15 PM | Akari Therapeutics (Filer)
| Form EFFECT | |
06/06/2023 7:59 AM | Akari Therapeutics (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |